new antiemetic drug developments formulations guidelines risk evaluation and controversies have occurred in the area of postoperative nausea and vomiting ponvthese developments have helped improve our understanding of the prevention and treatment of ponv in the postanesthesia care unit and after discharge home or to the hospital wardantiemetic drug research has resulted in the introduction of the secondgeneration 5hydroxytryptamine3 5ht3 receptor antagonist palonosetron and the neurokinin1 nk1 receptor antagonist aprepitant as well as new data on existing antiemeticsthe next frontier and need for further nausea and vomiting research and therapy is the area of postdischarge nausea and vomiting after the patient is discharged home from phase ii of the ambulatory stepdown unit or to the hospital wardantiemetic drug selection depends on efficacy cost safety and ease of dosingsafety concerns have arisen regarding the side effects of antiemetics specifically their effect on the ecg with prolongation of the qtc interval by the butyrophenones and the firstgeneration 5ht3 receptor antagonist class of antiemeticsthe impact of pharmocogenetics on antiemetic drug metabolism and their resulting efficacy has been correlated with genetic makeup affecting drug responsea discussion of ethics in ponv research has been initiated by the metaanalysis of ponv studiesto help guide antiemetic selection and ponv therapy for clinical practitioners the society of ambulatory anesthesia samba ponv consensus guidelines have been introduced and updated